E. A. Artamonova
Research Subjects
E. A. Artamonova has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Erovichenkov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences; Russian Medical Academy of Postgraduate Education
5 shared publications - S. K. Pylaeva
N.I. Pirogov Russian National Research Medical University Ministry of Health of Russia; M.P. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences
5 shared publications - A. U. Berestovskaia
Moscow Multidisciplinary Clinical Center «Kommunarka» of the Moscow Department of Health
3 shared publications - Aydar A. Ishmukhametov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia
3 shared publications - Denis Nikolaevich Protsenko
Pirogov Russian National Research Medical University
3 shared publications - Olga N. Solodovnikova
Moscow Multidisciplinary Clinical Center «Kommunarka
3 shared publications
Latest Publications
- Open Access
- 15 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 169-176
Neutralising and Non-neutralising Antibodies to SARS-CoV-2: Role during Infection and in the Evolution of Antigenic structure
Relevance. COVID-19, caused by the SARS-CoV-2 virus, remains a global public health threat despite the end of the pandemic. In the four years since the onset of the pandemic, the SARS-CoV-2 genome has undergone significant changes, particularly in the gene encoding the spike (S) protein. These changes resulted from the accumulation of immune responses in the human population, allowing the virus to evade the immune response. A significant proportion of the population was infected early in the pandemic or vaccinated with vaccines based on earlier variants of the virus. The emergence of new mutant variants raises concerns about the potential for severe COVID-19 in previously infected or vaccinated individuals.Аim. To examine the specifics of antibody formation, as well as the spectrum and functional activity of these antibodies in patients with COVID-19.Conclusions. Antibodies produced in response to infection or vaccination show diversity in spectrum and functional activity. Changes in the viral genome may reduce antibody effectiveness, highlighting the importance of monitoring new SARS-CoV-2 variants and developing adapted vaccines. These data will be key in shaping COVID-19 vaccination and treatment strategies in a changing epidemiological situation.
- 15 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 169-176
Open AccessNeutralising and Non-neutralising Antibodies to SARS-CoV-2: Role during Infection and in the Evolution of Antigenic structure
Relevance. COVID-19, caused by the SARS-CoV-2 virus, remains a global public health threat despite the end of the pandemic. In the four years since the onset of the pandemic, the SARS-CoV-2 genome has undergone significant changes, particularly in the gene encoding the spike (S) protein. These changes resulted from the accumulation of immune responses in the human population, allowing the virus to evade the immune response. A significant proportion of the population was infected early in the pandemic or vaccinated with vaccines based on earlier variants of the virus. The emergence of new mutant variants raises concerns about the potential for severe COVID-19 in previously infected or vaccinated individuals.Аim. To examine the specifics of antibody formation, as well as the spectrum and functional activity of these antibodies in patients with COVID-19.Conclusions. Antibodies produced in response to infection or vaccination show diversity in spectrum and functional activity. Changes in the viral genome may reduce antibody effectiveness, highlighting the importance of monitoring new SARS-CoV-2 variants and developing adapted vaccines. These data will be key in shaping COVID-19 vaccination and treatment strategies in a changing epidemiological situation.
- Open Access
- 6 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 63-72
Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
SARS-CoV-2 has been actively circulating in the human population since late 2019. During this time, the virus acquired more than 140 nucleotide mutations and 20 deletions per genome from the original variant identified in Wuhan. As the virus circulates, the proportion of re-infected individuals increases, but it is unclear how well neutralizing antibodies formed by infection with early variants neutralize the new Omicron variant lines. We analyzed the neutralizing activity of 286 sera from 286 adult patients with COVID-19 in 2020-2021, during the circulation of the prototypical lines and the Delta variant of SARS-CoV-2, against strains of the original lines and the Omicron ВА.1 and ХВВ.1.9. 2. About 10% of the sera of people who overexperienced COVID-19 while the prototypical strains were circulating and about 50% of people who overexperienced it while the Delta variant was circulating contain antibodies that neutralize Omicron ХВВ.1.9 was circulating in 2023. Thus, a fraction of people, regardless of age, who became infected in 2020-2021 have an antibody spectrum capable of neutralizing current and possibly related SARS-CoV-2 variants that will emerge in the near future. However, no strong positive correlation was found between IgG levels to RBD and NAТ titers to SARS-CoV-2 (R < 0.5), which may complicate serologic diagnosis of COVID-19 and lead to inappropriate assessment of human protection and the presence of an immune layer to SARS-CoV-2 in population-based studies.
- 6 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 63-72
Open AccessNeutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
SARS-CoV-2 has been actively circulating in the human population since late 2019. During this time, the virus acquired more than 140 nucleotide mutations and 20 deletions per genome from the original variant identified in Wuhan. As the virus circulates, the proportion of re-infected individuals increases, but it is unclear how well neutralizing antibodies formed by infection with early variants neutralize the new Omicron variant lines. We analyzed the neutralizing activity of 286 sera from 286 adult patients with COVID-19 in 2020-2021, during the circulation of the prototypical lines and the Delta variant of SARS-CoV-2, against strains of the original lines and the Omicron ВА.1 and ХВВ.1.9. 2. About 10% of the sera of people who overexperienced COVID-19 while the prototypical strains were circulating and about 50% of people who overexperienced it while the Delta variant was circulating contain antibodies that neutralize Omicron ХВВ.1.9 was circulating in 2023. Thus, a fraction of people, regardless of age, who became infected in 2020-2021 have an antibody spectrum capable of neutralizing current and possibly related SARS-CoV-2 variants that will emerge in the near future. However, no strong positive correlation was found between IgG levels to RBD and NAТ titers to SARS-CoV-2 (R < 0.5), which may complicate serologic diagnosis of COVID-19 and lead to inappropriate assessment of human protection and the presence of an immune layer to SARS-CoV-2 in population-based studies.
- Open Access
- 24 September 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (3) , 19-25
Clinical and epidemiological characteristics of imported intestinal infections in children
Клинико-эпидемиологическая характеристика завозных кишечных инфекций у детей
- 24 September 2024
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 23 (3) , 19-25
Open AccessClinical and epidemiological characteristics of imported intestinal infections in children
Клинико-эпидемиологическая характеристика завозных кишечных инфекций у детей
- Open Access
- 3 May 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (2) , 102-113
Current Strategies for Vaccine Prophylaxis of Lyme Disease
Relevance. Lyme disease (LD) remains an important public health problem, especially in Russia, where the incidence is consistently high. To date, there is still no available vaccine against LD, and prevention involves non-specific measures. Aim: to review the literature and summarise data on progress, approaches and strategies for LD vaccine development. Conclusions. The first LD vaccines were developed in the 1990s. An OspA-based vaccine (LYMErix) was commercially available in the early 2000s but not widely distributed. An important milestone in the development of LD vaccines was the shift from the development of monovalent vaccines based on a single type of outer surface protein to the development of multivalent combinations that provide protection against different Borrelia genospecies. A multivalent OspA-based vaccine (VLA15) is in phase III clinical trials and is likely to be the next LD vaccine available on the market. New genetic strategies for vaccine development, identification of new immunogens, and development of vaccines targeting different parts of the LD transmission cycle are of broad interest for further development of LD vaccines.
- 3 May 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (2) , 102-113
Open AccessCurrent Strategies for Vaccine Prophylaxis of Lyme Disease
Relevance. Lyme disease (LD) remains an important public health problem, especially in Russia, where the incidence is consistently high. To date, there is still no available vaccine against LD, and prevention involves non-specific measures. Aim: to review the literature and summarise data on progress, approaches and strategies for LD vaccine development. Conclusions. The first LD vaccines were developed in the 1990s. An OspA-based vaccine (LYMErix) was commercially available in the early 2000s but not widely distributed. An important milestone in the development of LD vaccines was the shift from the development of monovalent vaccines based on a single type of outer surface protein to the development of multivalent combinations that provide protection against different Borrelia genospecies. A multivalent OspA-based vaccine (VLA15) is in phase III clinical trials and is likely to be the next LD vaccine available on the market. New genetic strategies for vaccine development, identification of new immunogens, and development of vaccines targeting different parts of the LD transmission cycle are of broad interest for further development of LD vaccines.
- Open Access
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 12-17
Early warning system of clinical deterioration in pediatric patients with common cold
Раннее выявление риска клинического ухудшения у пациентов детского возраста при острых респираторных вирусных инфекциях
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 12-17
Open AccessEarly warning system of clinical deterioration in pediatric patients with common cold
Раннее выявление риска клинического ухудшения у пациентов детского возраста при острых респираторных вирусных инфекциях